LBDA

Nelotanserin for Potential Treatment of REM Sleep Behavior Disorder in LBD

What is this study about?

This trial is testing an experimental drug (called nelotanserin) to determine its effectiveness in treating REM sleep behavior disorder in people with Lewy body dementia (LBD).

What is involved?

The study begins with a “double-blind, placebo controlled” phase, meaning neither the researcher nor the person in the trial will know who is getting the study drug or a placebo.

Participants who complete the study may be eligible for an open-label extension in which all participants will receive nelotanserin.

Each participant will attend an initial screening visit plus 4 additional study visits over the course of approximately 10 weeks. Transportation assistance to and from study visits may be available.

Who can participate?

An individual may be able to take part in the trial if he/she*:

  • Is at least 50 years of age
  • Has been diagnosed with dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD)
  • Experiences frequent REM sleep behavior episodes (physically acting out dreams during sleep)

* additional eligibility criteria apply

Take the pre-screener to see if you qualify.

Study Sponsor:

Axovant Sciences, Ltd.

Still have questions?

For more information about this clinical trial, please contact (844) 221-3100 .